Rhinosinusitis is the mucosal inflammation of the nose and paranasal sinuses caused by bacteria lasting >10 days for up to 4 weeks, symptoms resolve completely and may either be persistent or severe.
It is often preceded by a viral upper respiratory tract infection.
Signs & symptoms are nonspecific and it is typically difficult to differentiate from viral upper respiratory tract infection.
Streptococcus pneumoniae is the most common cause followed by nontypeable Haemophilus influenzae.

Rhinosinusitis - Acute, Bacterial (Pediatric) References

  1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, Global Allergy and Asthma European Network, and AllerGen NCE Inc.). Allergy. 2008 Apr;63(Suppl 86):008-160. doi: 10.1111/j.1398-9995.2007.01620.x. PMID: 18331513
  2. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008 Aug;122(Suppl 2):S1-S84. doi: 10.1016/j.jaci.2008.06.003. PMID: 18662584
  3. American Academy of Pediatrics. Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical practice guideline: management of sinusitis. Pediatrics. 2001 Sep;108(3):798-808. http://pediatrics.aappublications.org/. PMID: 11533355
  4. Anon JB, Jacobs MR, Poole MD, et al; Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004 Jan;130(1)(Suppl):001-45. PMID: 14726904
  5. Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012 Apr;54(8):e72-e112. doi: 10.1093/cid/cir1043. Accessed 09 Oct 2013. PMID: 22438350
  6. Fokkens WJ, Lund VJ, Mullol J, et al; European Position Paper on Nasal Polyps group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007;20:1-136. PMID: 17844873
  7. Garbutt JM, Goldstein M, Gellman E, et al. A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis. Pediatrics. 2001 Apr;107(4):619-625. PMID: 11335733
  8. Green RJ. Symptomatic treatment of upper respiratory tract symptoms in children. S Afr Fam Pract. 2006;48(4):38-42
  9. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol. 2004 Dec;114(Suppl 6):S155-S212. PMID: 15577865
  10. Morris P, Leach A. WITHDRAWN: Antibiotics for persistent nasal discharge (rhinosinusitis) in children. Cochrane Database of Systematic Reviews. 2007 Jul(3). doi: 10.1002/14651858.CD001094.pub2. PMID: 17636651
  11. Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for Penicillin-allergic patients. Pediatrics. 2005 Apr;115(4):1048-1057. PMID: 15805383
  12. Piccirillo JF, Mager DE, Frisse ME, et al. Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis. J Am Med Assoc. 2001 Oct;286(15):1849-1856. PMID: 11597286
  13. Small CB, Bachert C, Lund VJ, et al. Judicious antibiotic use and intranasal corticosteroids in acute rhinosinusitis. Am J Med. 2007 Apr;120(4):289-294. PMID: 17398218
  14. Zacharisen M, Casper R. Pediatric sinusitis. Immunol Allergy Clin North Am. 2005 May;25(2):313-332. PMID: 15878458
  15. Gilbert DN, Moellering RC, Eliopoulos GM, et al. The Sanford guide to antimicrobial therapy. 40th. Sperryville, VA: Antimicrobial Therapy Inc; 2010.
  16. Rhinosinusitis. In: Hay WW, Levin MJ, Sondheimer JM, et al. Current diagnosis and treatment in pediatrics. 18th. New York: McGraw-Hill; 2007.
  17. Pappas DE, Hendley JD. Sinusitis. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of Pediatrics. 18th ed. Philadelphia: Saunders, Elsevier; 2007
  18. Brook I, Gooch WM III, Jenkins SG, et al. Medical management of acute bacterial sinusitis. Recommendations of a Clinical Advisory Committee on Pediatric and Adult Sinusitis. St. Louis, MO: Annals Publishing Company; 2000:20
  19. MedWormhttp://www.medworm.com/rss/index.php/Allergy-%26-Immunology/3/http://www.medworm.com/rss/medicalfeeds/specialities/Allergy-Immunology.xml
  20. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  21. MedWormhttp://www.medworm.com/rss/index.php/Respiratory-Medicine/40/http://www.medworm.com/rss/medicalfeeds/specialities/Respiratory-Medicine.xml
  22. Institute for Clinical Systems Improvement (ICSI). Health care guideline: diagnosis and treatment of respiratory illness in children and adults. http://www.icsi.org. 2007
  23. Acute Bacterial Sinusitis Guideline Team, Cincinnati Children’s Hospital Medical Center. Evidence-based care guideline for medical management of acute bacterial sinusitis in children 1 through 17 years of age. Guideline 16. Cincinnati, OH: Cincinnati Children’s Hospital Medical Center. http://www. antibioticos.msc.es/. Jul 2006.
  24. Alberta Medical Association. The diagnosis and management of acute bacterial sinusitis. Alberta Medical Association. http://www.albertadoctors.org. 2006.
  25. Lynch JS. What are the new guidelines for the management of bacterial rhinosinusitis?. Medscape. http://www.medscape.com/.
  26. American College of Physicians. The Physicians’ Information and Education Resource. Acute sinusitis. American College of Physicians. http://pier.acponline.org. 2007.
  27. Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics. 2013 Jul;132(1):e262-e280. doi: 10.1542/peds.2013-1071. PMID: 23796742
  28. Ip S, Fu L, Balk E, et al. (Tufts-New England Medical Center EPC, Boston,Mass). Update on acute bacterial rhinosinusitis. Evidence report/technology assessment No. 124. AHRQ Publication No.:05-E020-2. Contract No.:290-02-0022. Chap 3058. Agency for Healthcare Research and Quality. http://www.ncbi.nlm. nih.gov/books/bv.fcgi?rid= hstat1b. June 2005.
  29. Centers for Disease Control and Prevention. Pediatric treatment recommendations. CDC. https://www.cdc.gov/. Feb 2017.
  30. Wald ER. Acute bacterial rhinosinusitis in children: clinical features and diagnosis. UptoDate. https://www.uptodate.com/. Aug 2017.
  31. Wald ER. Acute bacterial rhinosinusitis in children: microbiology and treatment. UptoDate. https://www.uptodate.com/. Aug 2017.
  32. Esposito S, Bianchini S, Bosis S, et al. . A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J Transl Med. 2019 Aug;17(1):284. doi:10.1186/s12967-019-2040-y. PMID: 31443716
  33. Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020 Feb;58(Suppl S29):1-464. doi:10.4193/Rhin20.600. PMID: 32077450
  34. Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010 Feb;6(1):5-12. doi:10.1007/s12519-010-0001-x. PMID: 20143206
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Audrey Abella, 6 days ago
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.